

I. AMENDMENTS

Please amend the subject application as follows:

In the Claims:

1. (Amended) A method for producing cisplatin micelles, comprising:
 - a) combining a suitable buffer solution, cisplatin and a negatively charged phosphatidyl glycerol lipid derivative in a molar ratio of 1:1 to 1:2 to form a cisplatin mixture; and
 - b) combining the mixture of step a) with an effective amount of at least a 30% ethanol solution, thereby producing a cisplatin mixture in its aqua form in micelles.
2. (Amended) A method for producing cisplatin micelles, comprising:
 - a) combining a suitable buffer solution, cisplatin with an effective amount of at least a 30% ethanol solution to form a cisplatin/ethanol solution; and
 - b) combining the solution with a negatively charged phosphatidyl glycerol lipid derivative in a molar ratio of 1:1 to 1:2, thereby producing a cisplatin mixture in its aqua form in micelles.

5. (Amended) The method of claim 1 or 2, further comprising combining an effective amount of a free fusogenic peptide, a fusogenic peptide-lipid conjugate or a fusogenic peptide-PEG-HSPC conjugate to the mixture of step a) where the fusogenic peptide is derivatized with a stretch of 1-6 negatively-charged amino acids at the N or C- terminus and thus, able to bind electrostatically to the cisplatin mixture in its aqua form.

18. (Amended) The method of claim 9, wherein the lipid is selected from the group consisting of pre-made neutral liposomes comprising 10%-60% cholesterol, 40-90%

hydrogenated soy phosphatidylcholine (HSPC), 1-7% polyethyleucglycol (PEG)-HSPC and PEG-DSPE.

A³ cont'd
²³₁₂. (Amended) The method of claim ¹⁰₉, wherein the lipid comprises 10-60% cholesterol.

¹³₁₃. (Amended) A method for obtaining a cisplatin/lipid complex capable of evading macrophages and cells of the immune system when administered to a subject, the method comprising mixing an effective amount of the cisplatin micelles of claim ¹¹₁₀ with an effective amount of lipid selected from the group consisting of PEG-DSPE, PEG-DSPC and hyaluronic acid - DSPE.

Spec 4
A⁴
16. (Amended) An encapsulated cisplatin obtainable by the method of claim 11.

17. (Amended) An encapsulated cisplatin obtainable by the method of claim 13.

18. (Amended) A method for delivering cisplatin to a cell comprising contacting the cell with the encapsulated cisplatin of claim 16.

Spec 4
A⁵
22. (Amended) A method for targeting solid tumor cells and metastatic tumor cells in a subject comprising intravenous administration of an effective amount of the encapsulated cisplatin of claims 16 or 17.

⁹₂₃. (Amended) A method for penetrating the cell membrane of a tumor cell in a subject comprising administering an effective amount of the cisplatin micelle obtainable by the method of claim ⁸₇.

A⁶
²⁴₂₆. (New) The method of claim ¹⁰₉, wherein the vesicle-forming lipid is in solution or powder form.